Cogent Biosciences

Biotech & Life Sciences · Cambridge, United States · Founded 2014 · IPO 2018

Cogent Biosciences is a biotechnology company focused on the discovery and development of innovative small molecule therapies targeting rare, genetically driven diseases. The company serves patients with unmet medical needs, particularly those suffering from conditions that have limited treatment options. Operating within the biopharmaceutical market, Cogent Biosciences employs a research-driven business model, leveraging its scientific expertise to advance drug candidates through clinical trials. Revenue is primarily generated through the development and potential commercialization of these therapies, as well as through strategic partnerships and collaborations. The company has a strong financial position, with a year-end cash reserve of $242.2 million, supporting its ongoing research and development activities. Key initiatives include three clinical trials for their lead candidate, CGT9486, set to commence this year. Keywords: biotechnology, small molecule therapies, rare diseases, genetically driven, clinical trials, drug discovery, biopharmaceutical, research-driven, strategic partnerships, CGT9486.

Valuation $6.09B

Revenue $9.9M

Total funding $100–500M

Power Law Unicorn$1–10B valuation tier

Investors

19 investors on Cogent Biosciences's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 9 investors entered at this stage

New Leaf Venture Partners

Wellington Management

Seagen

Sectoral Asset Management

Novo Seeds

F-Prime

Cowen Group

Jennison Associates

Sanofi Ventures

Series B+ 10 investors entered at this stage

Square 1 Bank

Fairmount Funds Management

RTW Investments

Perceptive Advisors

Logos Capital

Commodore Capital

Atlas Venture

OrbiMed

Ally Bridge Group

SLR Capital Partners

Global footprint

Where Cogent Biosciences has talent and traffic

Workforce by country

3 countries with
team presence

🇺🇸 United States99.1%

🇬🇧 United Kingdom0.5%

🇩🇪 Germany0.5%

3 countries shown

Web traffic by country

23K monthly visits
across markets

🇺🇸 United States66.5%

🇮🇳 India10.4%

🇬🇧 United Kingdom6.5%

🇦🇺 Australia6.5%

🇨🇦 Canada4.8%

Top 5 markets shown

Talent graph

The shape of Cogent Biosciences's talent

Dealroom maps Cogent Biosciences's team person by person — pinpointing the standout operators and scoring them across the six dimensions investors underwrite. The counts and shape below are a public preview; the named individuals and exact scores live in the platform.

5 team members profilednamed & role-tagged by Dealroom

273 employeestotal headcount

2 executives & foundersidentified by name

DimensionScore

AI Talent

Engineering

Product

Go-to-market

Leadership

Research

Book a demo to unlock Cogent Biosciences's exact scores

Source: Dealroom Talent Intelligence. Public profiles show counts and the team's shape only — request a demo for the named individuals, per-person seniority and tenure, and team benchmarks vs peers.

Patent intelligence

$95k patent portfolio · 3 active families

Estimated portfolio value

$95k

<0.01% of market cap · 1414.3× smaller than top peer MacroGenics ($134M)

3 active patent families

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Market sentiment

What the market is saying about Cogent Biosciences

An AI-synthesized read of the highest-engagement posts about Cogent Biosciences on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Cogent Biosciences on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles